Cargando…

Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma

PURPOSE: To explore the imaging performance for discrimination of combined hepatocellular- cholangiocarcinoma (cHCC-CCA) and hepatocellular carcinoma (HCC). METHODS: In total, 35 patients with cHCC-CCA and a matched control group of HCC patients (n = 35) were included retrospectively. We quantitativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xue, Chang, Jing, Li, Ruili, Qi, Yu, Zeng, Xufen, Wang, Wei, Li, Hongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885771/
https://www.ncbi.nlm.nih.gov/pubmed/36727035
http://dx.doi.org/10.2147/JHC.S390820
_version_ 1784879998813863936
author Yang, Xue
Chang, Jing
Li, Ruili
Qi, Yu
Zeng, Xufen
Wang, Wei
Li, Hongjun
author_facet Yang, Xue
Chang, Jing
Li, Ruili
Qi, Yu
Zeng, Xufen
Wang, Wei
Li, Hongjun
author_sort Yang, Xue
collection PubMed
description PURPOSE: To explore the imaging performance for discrimination of combined hepatocellular- cholangiocarcinoma (cHCC-CCA) and hepatocellular carcinoma (HCC). METHODS: In total, 35 patients with cHCC-CCA and a matched control group of HCC patients (n = 35) were included retrospectively. We quantitatively evaluated the hypovascular component in tumor and qualitatively assessed LI-RADS features and other aggressive features to develop model for cHCC-CCA diagnose. Subgroup analyses were performed by tumor size and LI-RADS category. RESULTS: cHCC-CCA frequently showed a larger proportion (≥50%) of hypovascular areas followed by HCC (P = 0.000). Among those patients with ≥50% hypovascular areas, 8 patients did not present rim enhancement in atrial phase. The LI-RADS major features were more commonly observed in HCC (82.9–45.7%,), than cHCC-CCA (P = 0.003–0.022). The targetoid appearances and non-smooth margin frequently appeared in cHCC-CCA (34.3–63.9%), compared with HCC (P = 0.000–0.023). We developed a radiologic model based on ≥50% hypovascular component and delayed enhancement, which presented AUC of 0.821, accuracy of 80%. We also obtained good performance by radiologic model in LR-M group and tumor size <50mm group (AUC: 0.841 and 0.866, respectively). Combined group which included CA 19–9 and ≥50% hypovascular component and delayed enhancement did not improve the distinction performance between cHCC-CCA and HCC, which presented good performance of identifying cHCC-CCA in the LR-4/5 subgroup and tumor size ≥50 mm subgroup (AUC: 0.717, 0.730, respectively). cHCC-CCA group presented heterogeneous dominant pathology involving 15 of HCC, 7 of intrahepatic cholangiocarcinoma (iCCA) or cholangiolocellular carcinoma (CLC), 13 of intermediate cells component. Macrotrabecular appearances were higher in cHCC-CCA than that in HCC. The proportion of Hepa-1 was significantly higher in true negative (TN) patients (29 [93.5%]) and false negative (FN) patients (10 [100%]) than in true positive (TP) patients (16 [64%]; P = 0.036). CONCLUSION: Quantitative assessment of hypovascular component could help the discrimination of cHCC-CCA. Macrotrabecular appearances were more exhibited in cHCC-CCA than that in HCC.
format Online
Article
Text
id pubmed-9885771
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-98857712023-01-31 Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Yang, Xue Chang, Jing Li, Ruili Qi, Yu Zeng, Xufen Wang, Wei Li, Hongjun J Hepatocell Carcinoma Original Research PURPOSE: To explore the imaging performance for discrimination of combined hepatocellular- cholangiocarcinoma (cHCC-CCA) and hepatocellular carcinoma (HCC). METHODS: In total, 35 patients with cHCC-CCA and a matched control group of HCC patients (n = 35) were included retrospectively. We quantitatively evaluated the hypovascular component in tumor and qualitatively assessed LI-RADS features and other aggressive features to develop model for cHCC-CCA diagnose. Subgroup analyses were performed by tumor size and LI-RADS category. RESULTS: cHCC-CCA frequently showed a larger proportion (≥50%) of hypovascular areas followed by HCC (P = 0.000). Among those patients with ≥50% hypovascular areas, 8 patients did not present rim enhancement in atrial phase. The LI-RADS major features were more commonly observed in HCC (82.9–45.7%,), than cHCC-CCA (P = 0.003–0.022). The targetoid appearances and non-smooth margin frequently appeared in cHCC-CCA (34.3–63.9%), compared with HCC (P = 0.000–0.023). We developed a radiologic model based on ≥50% hypovascular component and delayed enhancement, which presented AUC of 0.821, accuracy of 80%. We also obtained good performance by radiologic model in LR-M group and tumor size <50mm group (AUC: 0.841 and 0.866, respectively). Combined group which included CA 19–9 and ≥50% hypovascular component and delayed enhancement did not improve the distinction performance between cHCC-CCA and HCC, which presented good performance of identifying cHCC-CCA in the LR-4/5 subgroup and tumor size ≥50 mm subgroup (AUC: 0.717, 0.730, respectively). cHCC-CCA group presented heterogeneous dominant pathology involving 15 of HCC, 7 of intrahepatic cholangiocarcinoma (iCCA) or cholangiolocellular carcinoma (CLC), 13 of intermediate cells component. Macrotrabecular appearances were higher in cHCC-CCA than that in HCC. The proportion of Hepa-1 was significantly higher in true negative (TN) patients (29 [93.5%]) and false negative (FN) patients (10 [100%]) than in true positive (TP) patients (16 [64%]; P = 0.036). CONCLUSION: Quantitative assessment of hypovascular component could help the discrimination of cHCC-CCA. Macrotrabecular appearances were more exhibited in cHCC-CCA than that in HCC. Dove 2023-01-26 /pmc/articles/PMC9885771/ /pubmed/36727035 http://dx.doi.org/10.2147/JHC.S390820 Text en © 2023 Yang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yang, Xue
Chang, Jing
Li, Ruili
Qi, Yu
Zeng, Xufen
Wang, Wei
Li, Hongjun
Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma
title Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma
title_full Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma
title_fullStr Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma
title_full_unstemmed Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma
title_short Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma
title_sort quantitative assessment of hypovascular component in arterial phase to help the discrimination of combined hepatocellular-cholangiocarcinoma and hepatocellular carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885771/
https://www.ncbi.nlm.nih.gov/pubmed/36727035
http://dx.doi.org/10.2147/JHC.S390820
work_keys_str_mv AT yangxue quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma
AT changjing quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma
AT liruili quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma
AT qiyu quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma
AT zengxufen quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma
AT wangwei quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma
AT lihongjun quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma